Under the agreement, T-MAXIMUM Biotech will get several CRISPR reagents from GenScript to aid in the development of its universal CAR-T products from discovery to commercialisation
GenScript Biotech and T-MAXIMUM partner on CAR-T cell therapy. (Credit: Julia Koblitz on Unsplash)
GenScript Biotech has collaborated with biotechnology company T-MAXIMUM Biotech to develop the latter’s development chimeric antigen receptor (CAR)-T cell therapy leveraging GenScript’s CRISPR nucleic acid reagents.
Under the agreement, T-MAXIMUM Biotech will get several CRISPR reagents from GenScript to aid in the development of its universal CAR-T products from discovery to commercialisation.
The collaboration with GenScript, a research tools and services provider, will help T-MAXIMUM Biotech to advance various products to the Phase 2 clinical research stage and bring products to market within the next five years.
T-MAXIMUM CEO Shang Xiaoyun said: “We are delighted to establish a strategic cooperation with GenScript. T-MAXIMUM focuses on recurrent high-grade gliomas without effective standard therapies and is committed to the development of universal CAR-T cell therapies.
“Gene editing reagents are crucial raw materials for the quality and efficacy of our products.
“We are confident that this collaboration will accelerate the regulatory processes in China and the United States, expediting T-MAXIMUM’s first product pipeline to benefit patients in need as soon as possible.”
The biotechnology company is developing MT027, a universal CAR-T cell therapy product, to treat recurrent high-grade gliomas.
T-MAXIMUM Biotech removes the TRAC and HLA genes using the CRISPR system and electroporation RNP technology to prevent GVHD and TCR receptor signal interference, lessen rejection symptoms, and extend the lifespan of CAR-T cells in the body.
In February this year, MT027 obtained US Food and Drug Administration (FDA) orphan drug designation (ODD) certification.
GenScript R&D and manufacturing VP Li Hong said: “We are honoured to collaborate with T-MAXIMUM Biotech. Our R&D-to-GMP-level sgRNA will support their UCAR-T products for solid tumours.
“While CAR-T cell therapies have made remarkable strides in haematological tumours, addressing the unmet need for solid tumours remains crucial. We look forward to the further achievements of T-MAXIMUM Biotech’s cell therapy products—and to bringing good news to more patients.”
US-based GenScript aims to offer prompt services to fulfil the demands of cell and gene therapy researchers at various stages and to hasten the growth of this expanding industry.